Contingent value rights (CVRs)

CVRs are issued to the shareholders of an acquired company, or to legacy shareholders in a reverse merger, entitling them to future payments tied to specific events: an approval, a partnering deal, or the sale of a legacy asset. They let two sides bridge a valuation gap without agreeing on the probability of the event.

In a business combination a CVR is contingent consideration, recorded at fair value on the acquisition date and remeasured each period through earnings. In an asset acquisition or a reverse recapitalization the analysis is more nuanced, and many CVRs are liabilities under ASC 480 or derivatives under ASC 815, again remeasured at fair value. Some are non-transferable and settled only in cash, which affects the conclusion.

The fair value depends on probability-weighted outcomes and discount rates, so each clinical update changes the liability. The finance team needs a valuation model and a plan for the quarterly disclosure.